The new initiative will address the unmet need for Caribbean-specific genomic research.

Oxford, UK – March 19, 2025 – – CariGenetics, in collaboration with Oxford Nanopore Technologies, has launched its Caribbean Genome Programme, the first large-scale genomic sequencing initiative in the region. This pioneering effort is set to address unmet need in advancing regional genetic research in the Caribbean, providing real-time, high throughput sequencing to address critical health disparities, starting with men’s health.

The Caribbean has been historically underrepresented in genomic studies, with many global databases omitting them entirely. The Caribbean Genome Programme will start address this by sequencing 1,000 men with and without disease across 10 islands in its initial phase—scaling to 100,000 individuals by the end of 2027—to improve understanding of genetic factors influencing prostate cancer and other health conditions.

For the first time, large-scale genome sequencing is being conducted within the region rather than samples being sent overseas for analysis. Powered by Oxford Nanopore’s real-time, accessible sequencing technology, CariGenetics is building local capacity for genetic research, ensuring faster insights and regional data ownership.

Dr. Carika Weldon, founder and CEO of CariGenetics, said:

“For too long, the Caribbean has been absent from the global genomics conversation. This programme will not only generate the first large-scale dataset for our communities but will also empower regional researchers with cutting-edge sequencing technology. Oxford Nanopore’s approach aligns perfectly with our mission to enable in-country sequencing and real-time genomic insights. We have been able to perform testing that usually take months to within hours.”

A new model for inclusive genomic research

CariGenetics is taking an innovation-led, private-sector approach to genomic research—moving beyond traditional academic models. This initiative is designed to attract mission-aligned investors, philanthropic donors, and family offices, ensuring long-term, impact-driven support for genomic health equity.

Dr. Gordon Sanghera, CEO of Oxford Nanopore Technologies, commented:

“We are delighted to collaborate with CariGenetics in this groundbreaking initiative. Oxford Nanopore’s technology is designed to enable rapid, information-rich DNA and RNA analysis anywhere in the world—including underserved regions like the Caribbean. Dr. Weldon’s leadership is inspiring, and we are excited to see the impact this programme will have both on genomic research and healthcare in the Caribbean region, as well as the global Caribbean diaspora.”

CariGenetics is actively seeking strategic partnerships to expand its rapid, local genomic research capabilities, supporting the growth of its sequencing initiatives across the Caribbean.

For more information, please contact media@nanoporetech.com or carika@carigenetics.com.

About CariGenetics

CariGenetics is pioneering accessible, high-impact genomic research in the Caribbean, bringing real-time sequencing capabilities to the region for the first time. Founded by Dr. Carika Weldon, CariGenetics is committed to closing the gap in global genetics and ensuring Caribbean populations are represented in biomedical research.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.oxfordnanopore.com